Nervous system

AppliedVR Completes Pivotal Trial Finding Virtual Reality Is a Holistic Treatment for Chronic Pain

Retrieved on: 
Wednesday, February 24, 2021
Mental health, Technology, MEN, Medical devices, General Health, Science, Consumer, Clinical trials, Alternative medicine, Health, Other Science, Research, Audio, Video, Other Health, Women, Seniors, Consumer electronics, Pain, Nervous system, Nociception, Pain management, Acute pain, Virtual reality, Chronic pain, Randomized controlled trial, Virtual reality therapy, Beth Darnall

AppliedVR , a pioneer advancing the next generation of digital medicine, today announced results from its pivotal randomized controlled trial (RCT), evaluating virtual reality (VR) therapy for treating chronic pain at home.

Key Points: 
  • AppliedVR , a pioneer advancing the next generation of digital medicine, today announced results from its pivotal randomized controlled trial (RCT), evaluating virtual reality (VR) therapy for treating chronic pain at home.
  • EaseVRx is an eight-week program delivered via a virtual reality medical device which teaches participants how to recognize and adjust cognitive, emotional, and physical responses to chronic pain using one session per day.
  • Already the most evidence-backed VR provider in healthcare, AppliedVR is engaged with multiple big-name insurers to evaluate its platform as a covered treatment for chronic pain.
  • AppliedVR is a leader in digital therapeutics, pioneering virtual reality-based treatments that address the complexity of chronic pain.

National Spine and Pain Centers Names Douglas Badertscher President

Retrieved on: 
Tuesday, February 23, 2021
Nervous system, Branches of biology, Symptoms and signs, Acute pain, Nociception, Pain, Suffering

ROCKVILLE, Md., Feb. 23, 2021 /PRNewswire/ --National Spine and Pain Centers (NSPC), the nation's leading network of interventional pain practices, announced today that Douglas P. Badertscher has joined its leadership team as administrative President.

Key Points: 
  • ROCKVILLE, Md., Feb. 23, 2021 /PRNewswire/ --National Spine and Pain Centers (NSPC), the nation's leading network of interventional pain practices, announced today that Douglas P. Badertscher has joined its leadership team as administrative President.
  • Most recently, Badertscher served as President and COO of Pain Specialists of America.
  • About National Spine and Pain Centers:
    For more than 30 years, NSPC affiliated physicians have been pioneers in the relief of chronic and acute pain through minimally invasive procedures and leading-edge clinical research.
  • Medical services provided by independently operated physician practices branded as National Spine and Pain Centers and other affiliated brands.

Celéri Health Announces Enrollment of First Patient in Study of Real World Outcomes® for Medtronic DTM™ Spinal Cord Stimulation (SCS)

Retrieved on: 
Tuesday, February 23, 2021
Branches of biology, Nervous system, Pain management, Neurotechnology, Nociception, Neural engineering, Spinal cord stimulator, Neuropathic pain, Medtronic, Chronic pain, Peripheral neuropathy, Pain

The clinical study is sponsored by Celri Health and is supported by Medtronics External Research Program.

Key Points: 
  • The clinical study is sponsored by Celri Health and is supported by Medtronics External Research Program.
  • DTM therapy is the first tailored SCS approach intentionally developed from a novel scientific concept and demonstrated in a RCT.
  • DTM SCS therapy is a proprietary spinal cord stimulation algorithm available to treat patients with chronic pain that is delivered as a programming option via the Medtronic Intellis platform.
  • Modulation of neuroglial interactions using differential target multiplexed spinal cord stimulation in an animal model of neuropathic pain.

OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammation

Retrieved on: 
Tuesday, February 23, 2021
Nervous system, Branches of biology, Pain management, Organ systems, Pain, Peripheral neuropathy, Chronic pain, Neuropathic pain

10,899,796 entitled Compounds and Methods for Treating Pain was issued by the United States Patent and Trademark Office (USPTO) on January 26, 2021.

Key Points: 
  • 10,899,796 entitled Compounds and Methods for Treating Pain was issued by the United States Patent and Trademark Office (USPTO) on January 26, 2021.
  • This patent covers a class of bovine adrenal medulla (BAM) peptides linked to specific lipids that demonstrate potential for treating symptoms of neuropathic pain, ocular pain, ocular inflammation and/or dry eye disease.
  • These licenses included the rights to the intellectual property (IP) estate covering composition-of-matter and methodology claims on these lipid-linked analogues.
  • OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.

KT Tape Launches KT Recovery+ Wave

Retrieved on: 
Monday, February 22, 2021
Health sciences, Branches of biology, Nervous system, Acute pain, Adhesive tape, Alternative medicine, Elastic therapeutic tape, Pseudoscience, Palliative care, KT, Pain management, Pain

AMERICAN FORK, Utah, Feb. 22, 2021 /PRNewswire/ -- KT Tape, a leader in drug-free pain relief, today announced the latest innovation in its recovery product line up: KT Recovery+ Wave (KT Wave).

Key Points: 
  • AMERICAN FORK, Utah, Feb. 22, 2021 /PRNewswire/ -- KT Tape, a leader in drug-free pain relief, today announced the latest innovation in its recovery product line up: KT Recovery+ Wave (KT Wave).
  • The new KT Recovery+ Wave uses sensation-free electromagnetic pulses, known clinically as pulsed shortwave therapy (PSWT), to reduce nerve hypersensitivity and relieve pain.
  • Utilizing technology 17 years in the making, KT Wave is a miniaturized, non-prescription product that makes PSWT portable and affordable.
  • For a limited time, enjoy 20% off of your KT Wave purchase from kttape.com/pages/kt-recovery-wave by using the code Wave20.

Healthcare AR and VR Innovations Report 2020: Medical Education, Surgical Planning, Surgery Guidance and Therapies - ResearchAndMarkets.com

Retrieved on: 
Monday, February 22, 2021
Health, Other Health, Virtual reality, Chronic pain, Nociception, Pain management, Sensory systems, Nervous system, Perception

The "Revolutionizing Future of Care Through Immersive Technologies" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Revolutionizing Future of Care Through Immersive Technologies" report has been added to ResearchAndMarkets.com's offering.
  • The scope of this GO-TE is global.
  • This GO-TE provides an overview of AR and VR, and the drivers and challenges impacting their adoption.
  • This GO-TE highlights the AR and VR-related innovations in areas such as medical education, surgical planning, surgery guidance and therapies for conditions including mental health and chronic pain.

PureHA Puts the Brakes on the Aging Process

Retrieved on: 
Monday, February 22, 2021
Nervous system, Branches of biology, Articles, Skin care, Nociception, Acute pain, Pain, Suffering, Cosmetics, Wellness, Health

FORT LAUDERDALE, Fla., Feb. 22, 2021 /PRNewswire/ --The aging process comes with a variety of side effects.

Key Points: 
  • FORT LAUDERDALE, Fla., Feb. 22, 2021 /PRNewswire/ --The aging process comes with a variety of side effects.
  • That's why Canadian health and wellness brand Revelox had everything from cosmetics to pain-relief in mind when they created PureHA.
  • PureHA addresses external aging concerns by rejuvenating skin and helping to promote the overall health of the body's largest organ.
  • PureHA has received positive reviews, with one even claiming that significant herniated pain was completely relieved "after only a week of taking PureHA."

Zoetis Receives European Commission Marketing Authorization for Solensia® (frunevetmab), a New Therapy for Feline Osteoarthritis Pain

Retrieved on: 
Monday, February 22, 2021
Biotechnology, Health, Veterinary, Pharmaceutical, Clinical trials, Nervous system, Branches of biology, Symptoms and signs, Acute pain, Arthritis, Skeletal disorders, ZTS, Feline, Cat, Pain, Osteoarthritis, Solensia, Zoetis

Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the marketing authorization for Solensia (frunevetmab), a new feline osteoarthritis treatment to alleviate pain.

Key Points: 
  • Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the marketing authorization for Solensia (frunevetmab), a new feline osteoarthritis treatment to alleviate pain.
  • OA pain in cats remains vastly undertreated, and Solensia is a prime example of our commitment to meaningful innovation in feline medicines.
  • By alleviating pain, Solensia helps generally improve physical activity level, sociability and quality of life of cats with OA.
  • A total of 76% of cat owners reported sustained improvement in signs of pain when their cats were treated with Solensia.

2021 Pipeline Insights on the Inflammation and Pain Post Cataract Surgery Industry - ResearchAndMarkets.com

Retrieved on: 
Friday, February 19, 2021
Pharmaceutical, Optical, Health, Surgery, Branches of biology, Nervous system, Clinical medicine, Eye, Ophthalmology, Vision, Acute pain, Cataract, Pain, Inflammation

This report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Inflammation and Pain Post Cataract Surgery pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Inflammation and Pain Post Cataract Surgery pipeline landscape.
  • A detailed picture of the Inflammation and Pain Post Cataract Surgery pipeline landscape is provided which includes the disease overview and Inflammation and Pain Post Cataract Surgery treatment guidelines.
  • Inflammation and Pain Post Cataract Surgery: Therapeutic Assessment
    This segment of the report provides insights about the different Inflammation and Pain Post Cataract Surgery drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Inflammation and Pain Post Cataract Surgery pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2020 Financial Results After the Close of Markets on Thursday, March 11, 2021

Retrieved on: 
Thursday, February 18, 2021
Nervous system, Branches of biology, Symptoms and signs, Communication, Forward-looking statement, Pain

The replay will be available approximately two hours after the call on Assertios investor website.

Key Points: 
  • The replay will be available approximately two hours after the call on Assertios investor website.
  • The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation.
  • These forward-looking statements relate to, among other things, future events or the future performance or operations of Assertio.
  • Nothing contained herein constitutes or will be deemed to constitute a forecast, projection or estimate of the future financial performance or expected results of Assertio.